Please assess the completion status of the following clinical trial:

Trial Title: DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meets I-SPY 2 TRIAL inclusion criteria~  * High-risk for recurrent disease~PATIENT CHARACTERISTICS:~* Able to tolerate imaging required by protocol~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diffusion Weighted-MRI (Type: EXPERIMENTAL): Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).